Noven maintained at buy by Jefferies

Jefferies & Co., Inc. analyst David Windley kept Noven Pharmaceuticals Inc. at a buy as investors focus on the rapid weekly growth in Daytrana prescriptions. Noven management is already addressing the factors that dampened gross margin, with gradual improvement likely, according to the analyst. The company reported second-quarter earnings per share of $0.14, 5 cents below Jefferies' estimate and consensus. Shares of the Miami-based pharmaceutical company were down 28 cents, or 1.35%, at $20.51, on volume of 277,299 shares versus the three-month running average of 197,486 shares. (Nasdaq: NOVN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.